Covered recipient · General Payments record
REGGIE DAVID PARLIER
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,903.60
- Reported across 172 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $264.11 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $97.58 | 5 |
| ABBVIE INC. | $44.29 | 3 |
| Esperion Therapeutics, Inc. | $32.04 | 2 |
| GlaxoSmithKline, LLC. | $17.14 | 1 |
| Abbott Laboratories | $16.97 | 1 |
| Amgen Inc. | $15.69 | 1 |
| Lilly USA, LLC | $13.83 | 1 |
| Merck Sharp & Dohme Corporation | $13.47 | 1 |
| Novo Nordisk AS | $13.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $16.97 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124955605 | CMS |
| ABBVIE INC. | $14.87 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105185460 | CMS |
| ABBVIE INC. | $15.67 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105185462 | CMS |
| ABBVIE INC. | $13.75 | 08/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105185464 | CMS |
| Amgen Inc. | $15.69 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117649272 | CMS |
| Esperion Therapeutics, Inc. | $18.93 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129449784 | CMS |
| Esperion Therapeutics, Inc. | $13.11 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129449786 | CMS |
| GlaxoSmithKline, LLC. | $17.14 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116106813 | CMS |
| Lilly USA, LLC | $13.83 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135383581 | CMS |
| Merck Sharp & Dohme LLC | $13.47 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141870451 | CMS |
| Novo Nordisk Inc | $13.10 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096819371 | CMS |
| PFIZER INC. | $25.16 | 01/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130994488 | CMS |
| PFIZER INC. | $13.51 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131145463 | CMS |
| PFIZER INC. | $15.66 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132012996 | CMS |
| PFIZER INC. | $13.40 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131791145 | CMS |
| PFIZER INC. | $29.85 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131853149 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.